BLOG

Fierce-Biotech

Pyxis debuts next-gen cancer ADCs from under Pfizer’s wing

After raising a monster $152 million in a series B round last month, Pfizer darling Pyxis Oncology is ready to share more details about what it’ll be working on with all that cash.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}